reference/7898018

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7898018

Outgoing Links

Predicate	Object
contentType	Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	30
issn	0003-4819
issueIdentifier	9
pageRange	621-30
publicationName	Annals of Internal Medicine
startingPage	621
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c9715a34c9ccde7ccc72cadee3277b94 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_266f09c09d1e3aa97cbfe9240f44f32b
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_84765ff7e5d6ba0db69d2011f3025267
bibliographicCitation	Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU; Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007 May 01;146(9):621–30. doi: 10.7326/0003-4819-146-9-200705010-00004. PMID: 17470830.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7bfed86e8096ff62d82428b92e0c87cf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f93e3b49396e016d202ec83666a493fe http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24efae8e030117b0bc2f2d8e45a77395 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d182fa774f35c857290f42a207aa0f4c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6223277e2e0d7dbc0f8297d860db9a84 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_edc2d268cce346d0dbae97b583f84c98 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f240ea9282baa8ebe68faeecaa691306 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ffec9a0b8b4e1bc833e6a5a9213116f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_92fda9eed9c2cb6da9068ade91369826 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_76bae3d0c504bbd085b65af6d844c878
date	2007-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/17470830 https://doi.org/10.7326/0003-4819-146-9-200705010-00004
isPartOf	https://portal.issn.org/resource/ISSN/0003-4819 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/596
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial
discusses	http://id.nlm.nih.gov/mesh/M0001333 http://id.nlm.nih.gov/mesh/M0024272 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0282056 http://id.nlm.nih.gov/mesh/M0017460 http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0003122 http://id.nlm.nih.gov/mesh/M0009322 http://id.nlm.nih.gov/mesh/M0022150
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D005938Q000627 http://id.nlm.nih.gov/mesh/D000911Q000627 http://id.nlm.nih.gov/mesh/D014409Q000037 http://id.nlm.nih.gov/mesh/D013700Q000188 http://id.nlm.nih.gov/mesh/D000893Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D013700Q000097 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D015850Q000097 http://id.nlm.nih.gov/mesh/D055502 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D011241Q000627 http://id.nlm.nih.gov/mesh/D002097Q000378 http://id.nlm.nih.gov/mesh/D001799 http://id.nlm.nih.gov/mesh/D011239Q000627 http://id.nlm.nih.gov/mesh/D000911Q000009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000069285 http://id.nlm.nih.gov/mesh/D000893Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D012074
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9381

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128812924

Total number of triples: 65.